Herein, we have summarized the most significant results that we have communicated from our laboratories in the last thirty years, highlighting the most potent and attractive ChEIs based hit(lead)-Multitarget Small Molecules, such as (S)-p-methoxytacripyrine (1), ASS234 (2), Contilisant (3), and Contilistat (4), that we have identified in the search for new chemical entities for the therapy of Alzheimer's disease.

2025-03-14·ACS Pharmacology & Translational Science

Contilisant-Belinostat Hybrids: Polyfunctionalized Indole Derivatives as Multineurotarget Drugs for the Potential Treatment of Alzheimer’s Disease

Article

作者: Wille, Timo ; Marco-Contelles, José ; Hansen, Finn K. ; Pietsch, Markus ; Elsinghorst, Paul W. ; Krasniqi, Vesa ; Porro-Pérez, Alicia ; Gütschow, Michael ; Eimermacher, Sophia ; Stegen, Philipp ; Horn, Gabriele ; Schäker-Hübner, Linda ; Toledano-Pinedo, Mireia ; Tan, Kathrin

In this work, we designed, synthesized, and evaluated two types of multineurotargeting compounds using a pharmacophore merging strategy, aiming to develop potential treatments for Alzheimer's disease. We combined belinostat, an FDA-approved unselective histone deacetylase (HDAC) inhibitor, with the 5-substituted indole core of contilisant, known for its antioxidant and neuroprotective properties as well as its potent inhibitory activity against monoamine oxidases (MAOs), acetylcholinesterase (AChE), and butyrylcholinesterase (BChE). Among these, compounds 8c (HDAC1, IC₅₀ = 0.019 μM; HDAC6, IC₅₀ = 0.040 μM; AChE, IC₅₀ = 20.06 μM; BChE, IC₅₀ = 17.10 μM; MAO-B, IC₅₀ = 2.14 μM), and 9c (HDAC1, IC₅₀ = 0.126 μM; HDAC6, IC₅₀ = 0.020 μM; AChE, IC₅₀ = 2.73 μM; BChE, IC₅₀ = 4.03 μM; MAO-B, IC₅₀ = 1.18 μM) emerged as the most promising candidates. These compounds warrant further investigation as potential treatments for Alzheimer's disease due to their unique inhibition profiles and favorable mode of inhibition.

2024-09-26·Journal of Medicinal Chemistry

Contilisant+Tubastatin A Hybrids: Polyfunctionalized Indole Derivatives as New HDAC Inhibitor-Based Multitarget Small Molecules with In Vitro and In Vivo Activity in Neurodegenerative Diseases

Article

作者: Paricio, Nuria ; Iriepa, Isabel ; Mora-Morell, Alba ; Schäker-Hübner, Linda ; Dong, Min ; Knez, Damijan ; Rodrìguez, Ania Canseco ; Więckowska, Anna ; Dobrydnev, Alexey V. ; Griñán-Ferré, Christian ; Hansen, Finn K. ; Romero, Fernando ; Satała, Grzegorz ; Sànchez-Pérez, Ana M ; Matheu, Ander ; Gobec, Stanislav ; Bautista-Aguilera, Òscar M. ; Handzlik, Jadwiga ; Sanchis, Inmaculada ; Porro-Pérez, Alicia ; Godyń, Justyna ; Marco-Contelles, José ; Solana-Manrique, Cristina ; Almendros, Pedro ; Toledano-Pinedo, Mireia ; Rodríguez-Fernández, M. Mercedes ; Bojarski, Andrzej J. ; Doroz-Płonka, Agata ; Pérez, Belén ; Artetxe-Zurutuza, Aizpea ; Bellver-Sanchis, Aina ; Wolak, Małgorzata ; Samadi, Abdelouahid ; Siwek, Agata

Herein, we describe the design, synthesis, and biological evaluation of 15 Contilisant+Tubastatin A hybrids. These ligands are polyfunctionalized indole derivatives developed by juxtaposing selected pharmacophoric moieties of Contilisant and Tubastatin A to act as multifunctional ligands. Compounds 3 and 4 were identified as potent HDAC6 inhibitors (IC₅₀ = 0.012 μM and 0.035 μM, respectively), so they were further evaluated in Drosophila and human cell models of Parkinson's disease (PD). Both compounds attenuated PD-like phenotypes, such as motor defects, oxidative stress, and mitochondrial dysfunction in PD model flies. Ligands 3 and 4 were also studied in the transgenic Caenorhabditis elegans CL2006 model of Alzheimer's disease (AD). Both compounds were nontoxic, did not induce undesirable animal functional changes, inhibited age-related paralysis, and improved cognition in the thrashing assay. These results highlight 3 and 4 as novel multifunctional ligands that improve the features of PD and AD hallmarks in the respective animal models.

100 项与 Contilisant 相关的药物交易

登录后查看更多信息